BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Anand Bhushan, Sumona Ghosh, Samsiddhi Bhattacharjee, Sreedhar Chinnaswamy. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus InfectionJournal of Interferon & Cytokine Research 2017; 37(8): 369 doi: 10.1089/jir.2017.0002
2
Stuart C. Gordon, Sheri Trudeau, Jia Li, Yueren Zhou, Loralee B. Rupp, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Yihe G. Daida, Mark A. Schmidt, Mei Lu. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United StatesJournal of Clinical Gastroenterology 2019; 53(1): 40 doi: 10.1097/MCG.0000000000000872
3
Figen Sarıgul, Murat Sayan, Ulku User, Nefise Oztoprak. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict RulesHepatitis Monthly 2019; (In Press) doi: 10.5812/hepatmon.62390
4
E. Gane, R. Nahass, V. Luketic, E. Asante-Appiah, P. Hwang, M. Robertson, J. Wahl, E. Barr, B. Haber. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patientsJournal of Viral Hepatitis 2017; 24(10): 895 doi: 10.1111/jvh.12719
5
Maia Butsashvili, Lia Gvinjilia, George Kamkamidze, David Metreveli, Shorena Dvali, Tamar Rukhadze, Amiran Gamkrelidze, Muazzam Nasrullah, Shaun Shadaker, Juliette Morgan, Francisco Averhoff. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in GeorgiaBMC Research Notes 2020; 13(1) doi: 10.1186/s13104-020-05173-4
6
Xi Ran, HuaiYi Xie, Wei Li. Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-AnalysisHepatitis Monthly 2020; 20(1) doi: 10.5812/hepatmon.98798
7
Qunying Han, Xiude Fan, Xiaoyun Wang, Ye Wang, Huan Deng, Xiaoge Zhang, Kun Zhang, Na Li, Zhengwen Liu. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world settingVirology Journal 2019; 16(1) doi: 10.1186/s12985-019-1184-y
8
Hilla Knobler, Stephen Malnick. Hepatitis C and insulin action: An intimate relationshipWorld Journal of Hepatology 2016; 8(2): 131-138 doi: 10.4254/wjh.v8.i2.131
9
Jia-Horng Kao, Sang Hoon Ahn, Rong-Nan Chien, Mong Cho, Wan-Long Chuang, Sook-Hyang Jeong, Chen-Hua Liu, Seung-Woon Paik. Urgency to treat patients with chronic hepatitis C in AsiaJournal of Gastroenterology and Hepatology 2017; 32(5): 966 doi: 10.1111/jgh.13709
10
Abhilasha Madhvi, Smita Hingane, Rajpal Srivastav, Nishant Joshi, Chandru Subramani, Rajagopalan Muthumohan, Renu Khasa, Shweta Varshney, Manjula Kalia, Sudhanshu Vrati, Milan Surjit, C. T. Ranjith-Kumar. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-04449-3
11
Steven W. Johnson, Dorothea K. Thompson, Brianne Raccor. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic InterventionsCurrent Infectious Disease Reports 2017; 19(6) doi: 10.1007/s11908-017-0578-5
12
Nikolaos Lougiakis, Efseveia Frakolaki, Panagiota Karmou, Nicole Pouli, Panagiotis Marakos, Vanesa Madan, Ralf Bartenschlager, Niki Vassilaki. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanismChemical Biology & Drug Design 2017; 90(3): 352 doi: 10.1111/cbdd.12966
13
Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in IndiaHepatology International 2019; 13(2): 173 doi: 10.1007/s12072-019-09927-6